Baseimmune develops vaccines that protect against current infectious diseases and future evolving variants. The company’s goal is to defend populations against future pandemics and emerging health threats.
Baseimmune is developing therapeutic vaccines that train the immune system to treat chronic diseases. The company's lead focus is fibrosis, a condition where scarring progressively damages organs like the lungs, liver, and kidneys, and where current treatments only slow disease progression.
Most antibody drugs target a single pathway, but chronic diseases involve multiple interconnected drivers - block one and the disease often routes around it. Baseimmune's computational platform designs "multi-epitope" antigens that combine multiple targets into a single vaccine construct, potentially delivering the effect of several antibody drugs through one treatment.
The company has two lead fibrosis programs in preclinical development: a B-cell vaccine for idiopathic pulmonary fibrosis (IPF) and a T-cell vaccine targeting fibrosis across multiple organs.
Baseimmune was founded in 2019 by Joshua Blight, now Chief Scientific Officer, who pioneered computational vaccine design at the University of Oxford's Jenner Institute. Kevin Walton joined as CEO in 2024, bringing experience from Moderna and public biotech leadership.
